Category:Pediatric
Status:Active
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
This study will combine three drugs: sorafenib, cyclophosphamide and topotecan. Adding sorafenib to cyclophosphamide and topotecan may increase the effectiveness of this combination. The investigat...
Diagnosis: Pediatric Neuroblastoma
Phase: 1
Protocol Number: 14-494
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer i...
Diagnosis: Pediatric Neuroblastoma
Phase: N/A
Protocol Number: 00-272
This phase III trial studies how well response and biology-based risk factor-guided therapy works in treating younger patients with non-high risk neuroblastoma. Sometimes a tumor may not need treat...
Diagnosis: Pediatric Neuroblastoma
Phase:
Protocol Number: 14-449
This proposal sets forth the platform for a Precision Medicine clinical trial through the New Approaches to Neuroblastoma Therapy (NANT) consortium. The plan is to utilize NANT's established m...
Diagnosis: Pediatric Neuroblastoma
Phase:
Protocol Number: 16-624
Study of Lorlatinib (PF-06463922)
Lorlatinib is a novel inhibitor across ALK variants, including those resistant to crizotinib. In this first pediatric phase 1 trial of lorlatinib, the drug will be utilized as a single agent and in...
Diagnosis: Pediatric Brain Tumor, Pediatric Neuroblastoma
Phase:
Protocol Number: 17-393
This is a two arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles viru...
Diagnosis: Pediatric Neuroblastoma, Pediatric Brain Tumor
Phase:
Protocol Number: 17-103
A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or re...
Diagnosis: Pediatric Neuroblastoma, Pediatric Brain Tumor
Phase:
Protocol Number: 16-509
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblasto...
Diagnosis: Pediatric Neuroblastoma
Phase:
Protocol Number: 18-718
131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease. In this pediatric phase 1 trial, 131I-MIBG w...
Diagnosis: Pediatric Neuroblastoma
Phase:
Protocol Number: 18-200